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IκBαSmooth muscle (SM) 22α, an actin-binding protein, is down-regulated in atherosclerotic arteries. Disruption of
SM22α promotes arterial inﬂammation through activation of reactive oxygen species (ROS)-mediated nuclear
factor (NF)-κB pathways. This study aimed to investigate the mechanisms by which SM22α regulates vascular
inﬂammatory response. The ligation injury model of SM22α−/−mice displayed up-regulation of inﬂammatory
moleculesMCP-1, VCAM-1, and ICAM-1 in the carotid arteries. Similar results were discovered in human athero-
sclerotic samples. In vitro studies, overexpression of SM22α attenuated TNF-α-induced IκBα phosphorylation
and degradation, accompanied by decreased NF-κB activity and reduced inﬂammatory molecule expression.
Using coimmunoprecipitation, we found that SM22α interacted with and stabilized IκBα in quiescent VSMCs.
Upon TNF-α stimulation, SM22αwas phosphorylated by casein kinase (CK) II at Thr139, leading to dissociation
of SM22α from IκBα, followed by IκBα degradation and NF-κB activation. Our ﬁndings demonstrate that SM22α
is a phosphorylation-regulated suppressor of IKK–IκBα–NF-κB signaling cascades. SM22αmay be a novel thera-
peutic target for human vascular diseases and other inﬂammatory conditions.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Inﬂammation has been considered as an important etiological factor
of cardiovascular diseases, such as atherosclerosis and restenosis [1].
The transcription factor NF-κB plays a central role in the regulation of
genes involved in inﬂammatory responses [2,3]. Activation of NF-κB is
controlled by inhibitor of NF-κB proteins (IκBα), which sequester the
majority of NF-κB in the cytoplasm as complexes by masking their
nuclear localization signals. Upon pro-inﬂammatory stimulation, IκBα
is phosphorylated by IκB kinases (IKK), and degraded via ubiquitin-
proteasome pathway, thus permitting nuclear translocation of the NF-
κB subunits and inducing inﬂammatory gene activation [4]. The inhibi-
tory activity of IκBα can be modulated by the cytoskeleton-associated
protein through physical interaction with IκBα rather than phosphory-
lation by IKKβ [5]. However, little is known about the adapter and reg-
ulation of targeting IκBα in inﬂammatory responses.
Smoothmuscle (SM) 22α, also known as transgelin, is a 22 kDa pro-
tein abundant in the smoothmuscle cells (SMCs) of vertebrates [6]. The
DNA and protein sequences of SM22α are highly conserved across spe-
cies, which shares 97% identity among mouse, rat, and human [7]. We+86 31186265557.
. This is an open access article underand others have demonstrated that SM22α binds to actin, and facilitates
actin ﬁlament assembly into bundles, which may enhance the contrac-
tility and mobility of VSMCs [8]. The activity of SM22α is necessary for
maintaining the differentiated phenotype of VSMCs [8]. Otherwise, it
contributes to the stabilization of cellular structure via interaction
with actin [9,10]. Although SM22α−/−mice displayed normal vascula-
ture development and function state, such as blood pressure and heart
rate, the role of SM22α may not be compensated under pathological
conditions [11]. Emerging evidence suggests an important role for
SM22α in pathogenesis of a variety of human diseases. The expression
of SM22α is downregulated in inﬂammation-related diseases, such as
atherosclerotic plaques, abdominal aortic aneurysms, and several
types of cancer [12]. Loss of SM22α in apolipoprotein E knockout mice
led to enlarged atherosclerotic lesions with prominent macrophage
inﬁltration, a sign of enhanced inﬂammation [13]. Our previous studies
revealed that overexpression of SM22α inhibited VSMC proliferation
and neointimal formation induced by balloon injury via blockade of
the Ras-ERK1/2 signaling pathway [14]. Furthermore, SM22α, as a
PKCδ-regulating and PKCδ-regulated adaptor protein,modulated vascu-
lar oxidative stress in vitro and in vivo through activation of PKCδ-
p47phox axis viamodulation of actin dynamics [15]. Ourﬁndings suggest
that SM22αmay act as an adapter or scaffold protein to modulate sig-
naling. More recently, the aortic transcriptomes of SM22α−/− micethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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atherosclerosis, because the knockout of Sm22α results in an increased
expression of pro-inﬂammatory genes in the aortas which are con-
trolled by NF-κB (RelA) [16]. However, the mechanism by which
disruption of SM22α activates NF-κB is not fully understood.
In this study, we demonstrated that SM22α interacted with and sta-
bilized IκBα to inhibit NF-κB p65 nuclear translocation. CKII-mediated
phosphorylation of SM22α promoted the dissociation of the IκBα–
SM22α complex, which led to IκBα phosphorylation and degradation.
These ﬁndings reveal a critical role for SM22α in controlling NF-κB ac-
tivity and vascular inﬂammation, and suggest that SM22αmay serve
as a new target to design therapeutic drug and to prevent further
organ damage in vascular inﬂammatory diseases.
2. Methods
2.1. Animals
The SM22α-knockout mice line (B6.129S6-Taglntm2(cre)Yec/J) which
has a Cre-recombinase gene inserted into the endogenous SM22α
locuswas purchased from the Jackson Laboratory [17]. Sprague–Dawley
rats were obtained from the Experimental Animal Center of HebeiMed-
ical University. Only male mice, at least 12 weeks of age, were used for
experiments. All animal procedures conformed to the Guide for the
Care and Use of Laboratory Animals published by the US National Insti-
tutes of Health (NIH Publication, 8th Edition, 2011), andwere approved
by the Institutional Animal Care and Use Committee of Hebei Medical
University.
2.2. Adventitial gene transfer and carotid artery ligation injury
The carotid artery injury of themicewas induced by complete liga-
tion of the left common carotid artery as previously described [18]. An-
esthesia wasmaintained by mask inhalation of isoﬂurane. The common
carotid artery was dissected free of the surrounding connective tissue
and Ad-GFP-SM22α (5 × 109 pfu/mL) or Ad-GFP (5 × 109 pfu/mL)
was suspended together in 50 μL pluronic F127 gel (25%wt/vol) and ap-
plied around the carotid artery. Being euthanized using intraperitoneal
overdose anesthesia with sodium pentobarbital (200–250 mg/kg). Ca-
rotid arteries were harvested 2 weeks after ligation.
2.3. Human subjects
The study was carried out in accordance with the ethical princi-
ples for medical research involving human subjects set out in the
Helsinki Declaration, and was approved by the ethical committee
at our institution. Carotid arteries with atherosclerotic plaque
were obtained from 8 autopsied patients with carotid atheroscle-
rotic plaques (males, average age, 75 ± 4.7 years). As controls,
nonatherosclerotic carotid arteries of similar size were obtained
from 8 autopsied patients (males, average age, 74 ± 5.2 years)
who died of nonatherosclerotic diseases. Each specimen was im-
mediately frozen in liquid nitrogen for RNA isolation. All patients
or their relatives gave informed consent prior to their participation
in the study.
2.4. Cell culture and treatment
Rat VSMCs were isolated from aortas of 80–100 gmale Sprague–
Dawley rats anesthetized intraperitoneally with urethane (1.5 g/kg
body weight) as described previously [19]. Mice were sacriﬁced by
cervical dislocation in order to obtain tissues to harvest VSMCs. The
VSMCs of wild-type and SM22α−/−mice were isolated from aortas
with 1% collagenase. The VSMCs were cultured in low glucose
DMEM supplemented with 20% FBS. Fetal bovine serum was ob-
tained from PAA Laboratories (Canadian Origin, NO. A15-751).Human embryonic kidney 293 cells were purchased from ATCC
and maintained in high glucose Dulbecco's modiﬁed Eagle's medi-
um supplemented with 10% FBS. Before stimulation with TNF-α
(10 ng/mL, PeproTech) and infection with adenoviruses, VSMCs
were incubated in serum-free medium for 24 h. For inhibitor studies,
cells were pretreated for 4 h with the CKII inhibitor CX-4945 (10 μmol/
L, Selleckchem) or vehicle control (0.1% DMSO, Sigma), before the addi-
tion of TNF-α. To block the degradation of ubiquitin, cellswere pretreated
with MG132 (10 μmol/L, Sigma) or vehicle control (0.1% DMSO) for 4 h,
and then stimulated by TNF-α.
2.5. Small interfering RNA (siRNA) transfection
The siRNA duplexes targeting rat SM22α mRNA (siSM22α), 5′-
GCUAGUGGAGUGGAUUGUATT-3′ and 5′-UACAAUCCACUCCACUAG
CTT-3′, and CKII siRNA (siCKII) 5′-CAAACUAUAAUCGUACAUC-3′ and
5′-GAUGUACGAUUAUAGUUUG-3′, were obtained from Invitrogen.
Scrambled siRNA (siCon) 5′-GCUAGAGUAGCGGUGAAUUCGTT-3′ and
5′-CGAAUUCAC CGCUACUCUAGCTT-3′ served as a negative control.
The siRNAs were transiently transfected into VSMCs using RNAi-MAX
reagent (Invitrogen).
2.6. Luciferase reporter assay
HEK293 cells were transfected by using Lipofectamine2000 reagent
(Invitrogen). The NF-κB luciferase reporter vector is designed to mea-
sure the binding of transcription factors to the κ enhancer. It contains
six tandem repeats of NF-κB binding site (TGGGGACTTTCCGC) as
promoters upstream of the luciferase transcription start site in the vec-
tor. Total concentration of transfected DNAwas corrected by addition of
pCDNA3.1 vector (Invitrogen). Luciferase activities were measured
using a Dual Luciferase Assay Kit (Promega). Speciﬁc promoter activity
was expressed as the relative activity ratio of ﬁreﬂy luciferase to Renilla
luciferase.
2.7. Oligonucleotide pull-down assay
The oligonucleotides containing NF-κB consensus sequences biotin-
5′-AGTTGAGGGGACTTTCCCAGG-3′were used. Nuclear protein extracts
(100 μg)were preclearedwith ImmunoPure streptavidin-agarose beads
(20 μL/sample; Promega) for 1 h at 4 °C. After centrifugation for 2min at
12,000 rpm, the supernatant was incubated with 100 pmol of biotinyl-
ated double-stranded oligonucleotides and 10 μg of poly (dI-dC)
overnight at 4 °C with gentle rocking. Then 30 μL of streptavidin-
agarose beads was added, followed by a further 1 h of incubation at
4 °C. The protein–DNA–streptavidin–agarose complex was washed 4
times with lysis buffer, separated on a 10% SDS-PAGE, and subjected
to Western blotting with different antibodies.
2.8. CKII activity assay
VSMCs were treated with TNF-α for different times, and then
harvested. CKII activity was detected by using the CKII Kinase Assay
Kit (CycLex, Cat# CY-1170) according to the manufacturer's manual.
2.9. Statistics
Data analysis was performed by using SPSS version 16.0. Data are
presented as the means ± SEM. Paired or unpaired data were com-
pared by Student's t tests. Differences among groups were analyzed
with one-way or two-way analysis of variance (ANOVA). For all sta-
tistical comparisons, P b 0.05 was considered signiﬁcant.
An expanded Materials and methods section is available in the On-
line Supplemental material.
Fig. 1. Disruption of SM22α aggravates vascular inﬂammation. A, Photomicrographs of
representative cross sections from carotid arteries of SM22α−/− and SM22α+/+ mice
14 days after ligation. Bars: 20 μm. The intimal areas and intima/media ratios were quan-
tiﬁed. B, Western blot analysis (left) and quantiﬁcation (right) of the MCP-1, ICAM-1 and
VCAM-1 protein levels in arteries from SM22α−/− and SM22α+/+mice with 14-day liga-
tion injury. A–B, Data are presented as themean± SEM, *P b 0.01 versus SM22α+/+mice
(n=6per group). C, Real-time RT-PCRof Sm22α and pro-inﬂammatorymoleculesmRNA
in human carotid arteries with plaques and nonatherosclerotic carotid arteries. The rela-
tive amount ofmRNAwasnormalized to the 18s rRNAcontent in each sample. Normalized
expression values are presented. Data are presented as the mean ± SEM, *P b 0.05 versus
nonatherosclerotic carotid arteries (n= 8 per group).
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3.1. Disruption of SM22α aggravates vascular inﬂammation
Previous studies found that SM22α−/− mice developed higher in-
ﬂammatory responses after artery injury [20]. In the present study, to
determine the roles of SM22α under pathological conditions, we
performed left carotid artery ligation in SM22α−/− mice and their
SM22α+/+ littermates. After 14 day ligation, the intima-to-media (I/
M) ratio was increased in the injured carotids from SM22α−/− micecomparedwith arteries from SM22α+/+ controls (Fig. 1A). UsingWest-
ern blot, we conﬁrmed that expression of inﬂammatory molecules, in-
cluding MCP-1, VCAM-1, and ICAM-1, was signiﬁcantly increased in
carotid arteries of SM22α−/− mice compared with their SM22α+/+
mice littermates (Fig. 1B). We then looked for evidence of SM22α in-
volvement in human vascular inﬂammation, and found that the expres-
sion of SM22α signiﬁcantly decreased in the carotid arteries with
atherosclerotic plaque, accompanied by increased expression of these
inﬂammatory molecules, compared with nonatherosclerotic carotid ar-
teries (Fig. 1C). These ﬁndings suggest that there is a strong correlation
between decreased SM22α expression and vascular inﬂammation. To
determine whether SM22α inhibits the vascular inﬂammation in vivo,
the carotid artery ligation model was prepared using SM22α−/−mice,
and transduced with either Ad-GFP-SM22α or Ad-GFP. The results
showed that the expression of inﬂammatory molecules was reduced
in the carotid artery rescuing SM22α expression after vascular injury
for 14 days, compared with the vehicle control (Fig. S1). The data
suggest that overexpression of SM22α improved injury-induced vascu-
lar inﬂammation in SM22α−/−mice in vivo.
3.2. SM22α inhibits NF-κB nuclear translocation and DNA binding activity
in VSMCs
We then deﬁne the causal relationship between the SM22α
expression and the cell inﬂammatory responses. We showed that
knockdown of SM22α increased TNF-α-induced expression of ICAM-
1, VCAM-1 and iNOS at the mRNA and protein levels in VSMCs
(Figs. S2A–B), whereas overexpression of SM22α decreased the expres-
sion of pro-inﬂammatory cytokines (Figs. S2C–D). NF-κB pathway
promotes vascular inﬂammation by inducing pro-inﬂammatory mole-
cules and adhesion proteins in vascular cells in an NF-κB nuclear
translocation-dependent fashion [21,22]. We found that the knock-
down of endogenous SM22α using speciﬁc siSM22α signiﬁcantly en-
hanced TNF-α-induced nuclear translocation of RelA/p65 (Fig. 2A).
The similar results were discovered in VSMCs isolated from
SM22α−/− mice (Figs. 2B, S3). Conversely, overexpression of SM22α
inhibited it (Figs. 2C, S4). To further address the inhibition of NF-κB ac-
tivation by SM22α, DNA binding and transcriptional activity of NF-κB
were analyzed in VSMCs stimulated with TNF-α. The results from aga-
rose oligonucleotide pull-down assay showed that overexpression of
SM22α reduced DNA binding activity of NF-κB (Fig. 2D). The inhibitory
effect of SM22α on NF-κB activity was further determined by transient-
ly co-expressing SM22α with a luciferase reporter driven by a 6-
tandem-repeat NF-κB element (Fig. 2E). These results suggest that
SM22α inhibits VSMC inﬂammatory responses through inhibition of
NF-κB activation, and may be a novel target for anti-inﬂammatory
intervention.
3.3. SM22α inhibits TNF-α-induced IκBα phosphorylation and degradation
It has been known that the IKK-mediated phosphorylation of IκBα is
a key early step of the nuclear translocation and activation of NF-κB,
which lead to its subsequent dissociation from NF-κB [4]. To determine
whether SM22α inhibiting NF-κB activation involves IKK repression,
VSMCs were transfected with siSM22α to knockdown or infected with
Ad-GFP-SM22α to overexpress SM22α. The overexpression of SM22α
markedly reduced TNF-α-induced IκBα phosphorylation and degrada-
tion compared with VSMCs infected with vehicle Ad-GFP (Fig. 3A).
Conversely, knockdown of endogenous SM22α expression resulted in
excessive phosphorylation and degradation of IκBα, which displayed
decreasing or even disappearing of IκBα compared with siCon
(Fig. 3B). Similarly, TNF-α-induced IκBα phosphorylation and degrada-
tion in VSMCs of SM22α−/−miceweremuchmore signiﬁcant than that
in WT mice (Fig. 3C). These results strongly suggest that SM22αmay
have ability to stabilize IκBα in VSMCs.
Fig. 2. SM22α inhibits NF-κB nuclear translocation and DNA binding activity in VSMCs. A, Western blot for NF-κB p65. VSMCs were transfected with siCon or siSM22α, and then treated
with (+) orwithout (−) TNF-α (10ng/mL) for 30min. LaminA/Cwasmeasured as a loading control for nuclear fractions. Data are presented as themean±SEM, #P b 0.01 versus siCon (−
) and *P b 0.01 versus siCon (+). B,Western blot for NF-κB p65. SM22α−/−mice VSMCswere treatedwith (+) orwithout (−) TNF-α. C,Western blot for NF-κB p65. VSMCswere infected
with Ad-GFP or Ad-GFP-SM22α, and then treated with (+) or without (−) TNF-α. B–C, Data are presented as the mean ± SEM, #P b 0.01 versus WT (−) or Ad-GFP (−) and *P b 0.01
versus WT (+) or Ad-GFP (+). D, Agarose oligonucleotide pull-down assay of NF-κB DNA-binding activity. VSMCs were infected with Ad-GFP or Ad-GFP-SM22α, and then treated
with (+) or without (−) TNF-α for 1 h. Input lanes correspond to the original cell extracts used for the oligonucleotide pull-down assay. Data are presented as the mean ± SEM,
#P b 0.01 versus Ad-GFP (−) and *P b 0.01 versus Ad-GFP (+). E, Luciferase assay in HEK293 cells transfected with the 6 × κB-luc, pEGFPC2 and pEGFPC2-SM22α followed by exposure
to TNF-α for 6 h. Ratios of transfected 6 × κB-luc and pEGFPC2-SM22α were 16:1, 4:1, 2:1 and 1:1. Data are presented as the mean ± SEM, *P b 0.01 versus TNF-α treated (6 × κB-luc
and pEGFPC2-SM22αwere 16:1).
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SM22α is an actin-binding protein. Previous study indicated that
IκBα physically interacted with a cytoskeleton-associated protein
through its signal response domain to modulate NF-κB activation [5].
These let us to hypothesize that SM22α interacts with IκBα to prevent
it from phosphorylation and degradation. To test this hypothesis, we
performed cross-coimmunoprecipitation using anti-IκBα and anti-
SM22α antibodies. The results showed that IκBα was associated with
SM22α in quiescent VSMCs, and was almost dissociated from SM22α
following TNF-α stimulation (Fig. 4A). This interaction was also
conﬁrmed by coimmunoprecipitation experiments in HEK293 cells
(Fig. 4B). Furthermore, VSMCs of SM22α−/− mice infected with Ad-
GFP-SM22α to rescue expression of SM22α displayed a marked reduc-
tion of the interaction between SM22α and IκBα upon TNF-α stimula-
tion (Fig. 4C). In addition, we also showed that SM22α bound to IκBα
of IκBα–NF-κB complex at normal expression levels using cross-coimmunoprecipitation (Fig. S5). Collectively, these results indicate
that SM22α forms a complex with IκBα under basal conditions, which
may be disrupted by TNF-α stimulation.
3.5. CKII mediates TNF-α-induced SM22α phosphorylation
To elucidate themechanism by which TNF-α induces dissociation of
SM22α from IκBα, we focused on the effect of posttranslational modiﬁ-
cation of SM22α on interaction between the both proteins. Based on the
two potential CKII consensus target motifs (S/T-X-X-D/E) in SM22α
structure [23], we ﬁrst measured CKII activity in VSMCs upon TNF-α
stimulation, and found that CKII activity was enhanced in cells after
treatment with TNF-α (Fig. S6). We then sought to determine whether
TNF-α induces SM22α phosphorylation in VSMCs. The results showed
that the phosphorylation of SM22α at Ser and Thr sites increased,
while total SM22α levels did not change during short-time TNF-α stim-
ulation (Figs. 5A, S7A). The pre-incubation with CX-4945, a CKII
Fig. 3. SM22α inhibits TNF-α-induced IκBα phosphorylation and degradation. A,Western blot for NF-κB signaling-related proteins. VSMCswere infectedwith Ad-GFP or Ad-GFP-SM22α,
and then treated with TNF-α for indicated times. Endogenous SM22α is 22 kDa (lower band), and GFP-tagged SM22α is 49 kDa (upper bands). Data are presented as the mean ± SEM,
#P b 0.01 versus Ad-GFP (0min), *P b 0.01 versus Ad-GFP (5min) and $P b 0.01 versus Ad-GFP (15min). B, VSMCs were transfected by siCon or siSM22α, and then treatedwith TNF-α for
indicated times. Data are presented as themean± SEM, #P b 0.01 versus siCon (0min), *P b 0.01 versus siCon (5min) and $P b 0.01 versus siCon (15min). C,Western blot for p-IκBα and
IκBα. Data are presented as the mean ± SEM, #P b 0.01 versus WT (−) and *P b 0.01 versus WT (+).
195Y.-N. Shu et al. / Journal of Molecular and Cellular Cardiology 84 (2015) 191–199inhibitor, signiﬁcantly attenuated TNF-α-induced phosphorylation of
SM22α at Thr but not Ser site (Figs. 5B, S7B). To verify this argument,
the speciﬁc CKII siRNA or a dominant-negative form of CKII (CKIIDN)
was transfected into VSMCs to disrupt CKII. We showed that disruption
of CKII abolished TNF-α-induced Thr phosphorylation of SM22α
(Figs. 5C–D, S7C–D). In addition, in a rescue experiment, re-
expression of CKII could restore TNF-α-induced SM22α phosphoryla-
tion in CKII-knocked down VSMCs (Figs. 5E, S7E). Furthermore,
SM22α WT and the mutants containing CKII site were transducted
into the VSMCs of SM22α−/−mice. We observed the phosphorylation
of SM22αWT, but not themutants of T139D (tomimic threonine phos-
phorylation) or T139A (to inhibit SM22α phosphorylation) (Figs. 5F,
S7F), suggesting that CKII may selectively phosphorylate SM22α
Thr139 in response to TNF-α stimulation. These data indicate that CKII
mediates TNF-α-induced phosphorylation of SM22α in VSMCs.3.6. SM22α Thr 139 phosphorylation results in dissociation of SM22α from
IκBα
To determine that CKII-mediated Thr 139 phosphorylation results in
dissociation of SM22α from IκBα, we detected the interaction of IκBα
with SM22α WT, as well as T139D and T139A mutants using
coimmunoprecipitation. SM22α T139D mutant revealed a reduced in-
teraction with IκBα, while SM22α T139A had an increase in binding
to IκBα comparedwith SM22αWT (Fig. 6A), suggesting that phosphor-
ylation of SM22α is required for IκBα dissociation. To assess whether
this dissociation contributes to IκBα phosphorylation and degradation,
SM22αWT and these two phosphorylation mutants were transducted
into SM22α−/− mice VSMCs. SM22α T139A mutant markedly de-
creased TNF-α-induced IκBα phosphorylation and degradation com-
pared to SM22α WT or T139D mutant, accompanied by decreased
Fig. 4. SM22α interacts with and stabilizes IκBα. A, VSMCswere pretreatedwith the proteasome inhibitor MG132 (10 μmol/L) or vehicle control (0.1% DMSO), and then treatedwith TNF-
α for 15min. The graph showed the quantiﬁcation of SM22α–IκBα interaction, data are presented as themean±SEM, *P b 0.05 versus 0min. B, HEK293 cellswere transfectedwith GFP or
GFP-tagged-SM22α. C, SM22α−/−mice VSMCs were infectedwith Ad-GFP-SM22α and pretreated with MG132, and then treatedwith TNF-α for 15 min. The anti-SM22α, anti-IκBα and
anti-GFP antibodies were used for immunoprecipitation (IP) or Western blot (IB). Input lanes correspond to the original cell extracts used for the immunoprecipitation assays. IgG was
used as negative control. The graph showed the quantiﬁcation of SM22α-IκBα interaction, data are presented as the mean ± SEM, *P b 0.01 versus control.
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dicate that the phosphorylation-mediated dissociation of SM22α from
IκBα facilitates IκBα phosphorylation and degradation, and subsequent
NF-κB nuclear translocation upon TNF-α stimulation (Fig. 6C).We iden-
tify a novel regulatorymechanism bywhich the degree of inﬂammation
is controlled by SM22α expression.
4. Discussion
Our recent studies have demonstrated that SM22α was an anti-
proliferation factor and molecular switch for oxidative stress in VSMCs[14,15]. The previous study demonstrated that vascular inﬂammation
was aggravated in SM22α−/− mice compared with wild-type mice
[20]. The present in vitro and in vivo study showed that SM22α was a
novel suppressor of vascular inﬂammation, demonstrating that overex-
pression of SM22αwas sufﬁcient to cause the repression of NF-κB activ-
ity and pro-inﬂammatory molecular expression. We found that
endogenous SM22α inhibited RelA/p65 nuclear translocation via bind-
ing to and stabilizing IκBα in the cytoplasm. The interaction of SM22α
with IκBα was regulated by SM22α phosphorylation status upon TNF-
α stimulation. Thus, SM22α is identiﬁed as a phosphorylation-
regulated suppressor of NF-κB, which may play a functional role in
Fig. 5. CKII mediates TNF-α-induced SM22α phosphorylation. A–F, Immunoprecipitation (IP) and Western blot (WB) for serine/threonine phosphorylation (p-Ser/p-Thr) of SM22α. A,
VSMCswere treatedwith TNF-α for indicated times. B, VSMCswere pretreatedwith CKII inhibitor CX-4945 (10 μmol/L) or vehicle control (0.1% DMSO), and then treatedwith or without
TNF-α for 15min. C, VSMCs were transfected ﬁrst with CKII siRNA for 24 h, then transfectedwith dominant-negativemutant form of CKII (pcDNA3.1-His-CKII DN) or pcDNA3.1-His-CKII,
and cell were treatedwith TNF-α. D, VSMCs were transfected by siCon or siCKII, and then treatedwith TNF-α. E, VSMCs were transfected by siCon or siCKII, and then rescued with CKII. F,
VSMCs of SM22α−/−mice were transfected with SM22αWT or its mutants, and then treated with TNF-α. The anti-p-Ser and anti-p-Thr antibodies were used for immunoprecipitation
(IP), anti-SM22α and anti-GFP antibodies were used for Western blot (IB). Input lanes correspond to the original cell extracts used for the immunoprecipitation assays. IgG was used as
negative control.
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depicting the role of SM22α in cellular responses to TNF-α is proposed
in Fig. 6C, which displays an intriguing link between CKII, SM22α, and
IκBα, related with modulation of NF-κB activity. Our study suggested
that SM22α bonds to signal molecules and regulated their functions
by itself phosphorylation.
We note thatmore studies support a role for SM22α in smoothmus-
cle biology. Speciﬁcally, deletion of SM22α delayed the downregulation
of SMC differentiation markers and enhanced neointimal formation
[14]. However, the role of SM22α in a chronic vascular inﬂammation
like experimental atherogenesis remains an important unanswered
question. Lili et al. [20] found SM22α−/− mice developed higher
inﬂammatory responses after artery injury, and proposed that disrup-
tion of SM22α expression in stressed VSMCs results in increased ROS
production, thereby leading to NF-κB activation. Our data conﬁrm that
SM22α is a direct regulator of NF-κB. SM22α−/−mice may be a sensi-
tive model of early vascular inﬂammation [16]. Importantly, these ﬁnd-
ings may also shed more light on the role of downregulation of SM22α
in cancers, abdominal aortic aneurysm, atherosclerosis and other in-
ﬂammatory vascular diseases. Therefore, homeostasis balance of
SM22α expression may serve as a therapeutic strategy to repress the
dysregulated inﬂammatory responses in arterial diseases as well as in
other diseases. The precise mechanism underlying down-regulation of
SM22α in inﬂammatory responses is worthy of further investigation.Regardless, the currentwork, coupledwith these previous observations,
indicates that SM22α is a novel modulator of vessel homeostasis in
health and diseases.
It was reported that Wiskott–Aldrich syndrome (WAS) protein, a
regulator of actin cytoskeleton, regulates nuclear translocation of
NFAT2 and NF-κB p65 [24]. Gabriel et al. [25] have shown that overex-
pression of thymosin β4, an actin-binding protein, suppresses TNF-α-
induced NF-κB activation in HCECs. In addition, up-regulation of NF-
κB was found in human intestinal epithelial cells and monocytic cells
following cytoskeleton depolymerization by cytochalasin D [26,27], im-
plying that actin dynamics affects NF-κB activity. Our current study
provides evidence that SM22α directlymodulates inﬂammatory signal-
ing molecule activity in inﬂammatory responses of VSMCs. SM22α
interacted with IκBα in quiescent cells, and effectively prevented IκBα
from phosphorylation and degradation, which allowed IκBα to trap
RelA/p65 in the cytoplasm.Moreover, this interaction seems to increase
the stability and ability of IκBα to associate with p65. Our ﬁndings elu-
cidated a novel mechanism by which SM22α inhibits NF-κB activation
via targeting IκBα as a partner, and explained its beneﬁcial actions in
the diverse pathologies.
The activity and function of proteins are regulated by posttranslation
modiﬁcation. CKII is a ubiquitously expressed and constitutively active
serine–threonine kinase that exists in various cells [28]. CKII-mediated
phosphorylation of IκBα has been implicated in the basal and signal-
Fig. 6. SM22α Thr 139 phosphorylation results in dissociation of SM22α from IκBα. A, Coimmunoprecipitation for the interaction of IκBαwith the WT and mutants of SM22α. VSMCs of
SM22α−/−mice were transfectedwith SM22αWT or its mutants, pretreatedwithMG132, and then treatedwith TNF-α (+) for 15min. Data are presented as themean± SEM, *P b 0.05
versus GFP-SM22α T139D (+). The anti-IκBα and anti-GFP antibodies were used for immunoprecipitation (IP) or Western blot (IB). Input lanes correspond to the original cell extracts
used for the immunoprecipitation assays. IgG was used as negative control. B, Western blot for p-IκBα and IκBα, and p65 nuclear translocation. Lamin A/C was used as a loading control
of nuclear fraction. Data are presented as themean± SEM, *P b 0.05 versus GFP-SM22α T139D (+). C, Diagram depicting the role of SM22α in response to TNF-α in VSMCs. Upon TNF-α
stimulation, SM22α is phosphorylated by CKII, and subsequently dissociated from IκBα, which promotes IκBα phosphorylation and degradation, and then NF-κB nuclear translocation to
activate the transcriptions of inﬂammatory genes.
198 Y.-N. Shu et al. / Journal of Molecular and Cellular Cardiology 84 (2015) 191–199dependent turnover of free and NF-κB-bound IκBα [29]. Previous work
has revealed that CKII may be involved in various steps of the NF-κB ac-
tivation process [30]. In the present study, we showed that CKII de-
creased IκBα stability via direct modiﬁcation of SM22α, and
knockdown of CKII reduced TNF-α-induced IκBα phosphorylation and
degradation in VSMCs (Fig. S8). Phosphorylation of SM22α at Thr139
by CKII resulted in its dissociation from IκBα, and subsequent IκBα
phosphorylation and degradation in VSMCs. The possible explanation
for this is that IKK target site in IκBα may be masked by SM22α.
These ﬁndings suggest that SM22α is required for stabilization of
IκBα–NF-κB inhibitory complex in VSMCs. Although the contribution
of SOD2 production to NF-κB activation has been suggested in the in-
jured carotids of SM22α−/−mice [20], in the present study, we found
that CKII and SM22α T139A mutant did not affect the TNFα-induced
SOD2 expression (Fig. S9). One possible explanation is the phosphoryla-
tion of SM22α is not involved in regulation of SOD2 expression.
In summary, we identiﬁed that SM22α is a new operating point for
NF-κB activation and vascular inﬂammation. The phosphorylation of
SM22α switches IKK–IκBα–NF-κB signaling cascades. SM22α is essen-
tial for maintaining a low inﬂammatory state in VSMCs in vitro orin vivo. Our ﬁndings demonstrate that VSMCs have the potential to con-
trol inﬂammatory damage. The exploitation for the anti-inﬂammation
function of SM22αmay lead to the development of new therapeutics
for human vascular disease and other inﬂammatory conditions.
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